InvestmentAug 6, 2026, 07:04 AM
Tarsus Pharmaceuticals Secures $125M PIPE Financing
AI Summary
Tarsus Pharmaceuticals, Inc. announced it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing, expected to generate approximately $125.0 million in gross proceeds. The financing includes participation from existing Alkeus Pharmaceuticals investors and new and existing Tarsus investors. The company plans to use the net proceeds to fund clinical development, commercial activities, and for general corporate purposes, following its earlier announcement of the pending acquisition of Alkeus.
Key Highlights
- Tarsus Pharmaceuticals secured approximately $125.0 million in gross proceeds from a PIPE financing.
- The financing includes participation from existing Alkeus investors (TCGX, Bain Capital Life Sciences, Wellington Management) and new/existing Tarsus investors (ADAR1 Capital Management, Sirenia Capital Management LP, RTW Investments, Vestal Point Capital).
- Tarsus is selling 2,098,519 shares of common stock at $56.00 per share.
- The company is also selling pre-funded warrants to purchase 133,625 shares at $55.9999 per warrant, with an exercise price of $0.0001 per share.
- The PIPE financing is expected to close on August 7, 2026, subject to customary closing conditions.
- Net proceeds will fund clinical development, commercial activities, and general corporate purposes.
Price Impact
More from TARS